This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Testing newborn babies for sepsis could become faster and more accurate, reducing complications and deaths, thanks to the development of a Western Australia–led point-of-care neonatal sepsis test.
Murdoch University Professor Andrew Currie, who is leading the project in partnership with Child and Adolescent Health Service clinical professor Tobias Strunk at King Edward Memorial Hospital Neonatology Services, said neonatal sepsis contributes to significant morbidity and mortality annually in Australia.
"Neonatal sepsis is a critical global health challenge demanding urgent attention in Australia, especially in remote locations where delayed diagnoses are experienced," Currie said.
"Existing early diagnostic blood tests are limited and require time-consuming hospital-based analysis rarely found outside tertiary hospitals, particularly in low- to middle-income countries.
"Delayed or incorrect diagnosis increases mortality risk, long-term adverse outcomes and inappropriate antibiotic use."
Currie and his team are developing PreSep-4, a rapid point-of-care blood test for neonatal sepsis. PreSep-4 is compatible with cutting-edge Australian lateral flow assay (LFA) detection technology.
The test uses four biomarkers to achieve more than 95% accuracy in diagnosing neonatal sepsis at the first suspicion of sepsis, up from the current 60% accuracy rate, and won't require any specialist equipment to perform.
The biomarkers used are key molecules in the sepsis pathway, identified through advanced proteomics and a machine learning–based diagnostic selection pipeline. These were discovered in WA newborns enrolled in the international PROTECT trial led by Strunk.
Source link
